2020
Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members
Diaz MJ, Chobrutskiy BI, Zaman S, Blanck G. Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members. Cancer Treatment And Research Communications 2020, 24: 100196. PMID: 32769037, DOI: 10.1016/j.ctarc.2020.100196.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAftercareAntineoplastic Agents, ImmunologicalBiomarkers, TumorButyrophilinsColorectal NeoplasmsComplementarity Determining RegionsComputational BiologyDisease-Free SurvivalExomeGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateReceptors, Antigen, B-CellReceptors, Antigen, T-CellRecombination, GeneticRNA-SeqSurvival RateConceptsSurvival rateLung cancerColon cancerImmune receptor recombinationsWorse survival rateCancer survival ratesCases of melanomaBetter survival rateB cell receptorFamily membersSurvival distinctionsCancer Genome AtlasImmunotherapy approachesColorectal adenocarcinomaT cellsImmunogenomics studiesCancer typesCancerConsistent associationHigh expressionGenome AtlasImmune receptorsImmunogenomic featuresMelanomaCancer exomes
2019
Targeting Trop-2 in solid tumors: future prospects
Zaman S, Jadid H, Denson AC, Gray JE. Targeting Trop-2 in solid tumors: future prospects. OncoTargets And Therapy 2019, 12: 1781-1790. PMID: 30881031, PMCID: PMC6402435, DOI: 10.2147/ott.s162447.Peer-Reviewed Original ResearchAntibody-drug conjugatesTrop-2Clinical benefitClinical trialsTumor typesPlatinum-resistant urothelial cancerSmall cell lung cancerMultiple early-phase clinical trialsTriple-negative breast cancerEarly phase clinical trialsLimited treatment optionsTrop-2 expressionMultiple tumor typesUrothelial cancerTreatment optionsLung cancerBreast cancerSolid tumorsBaseline levelsCancer typesClinical useUpregulated expressionCancerTumorsNormal cells